NM_000059.4(BRCA2):c.3646T>C (p.Phe1216Leu) AND Hereditary cancer-predisposing syndrome
- Germline classification:
- Uncertain significance (1 submission)
- Last evaluated:
- Apr 20, 2023
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV003293412.2
Allele description [Variation Report for NM_000059.4(BRCA2):c.3646T>C (p.Phe1216Leu)]
NM_000059.4(BRCA2):c.3646T>C (p.Phe1216Leu)
Condition(s)
- Name:
- Hereditary cancer-predisposing syndrome
- Synonyms:
- Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
- Identifiers:
- MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672
-
D014042 (1)
MeSH
-
Tolazamide
TolazamideA sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.<br/>Year introduced: 1973(1964)MeSH
-
GBE1 [Lynx rufus]
GBE1 [Lynx rufus]Gene ID:124526406Gene
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Sep 1, 2024